Skip to main content

Advertisement

Log in

MRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

The combination of gemcitabine and cisplatin has been shown previously to elicit a synergistic therapeutic effect on bladder cancer cell lines and result in reduced cell survival. However, the precise mechanism by which cells die has not been elucidated. Cell cycle-related genes are the predominant targets of chemotherapeutic protocols. Therefore, molecular biomarkers that are predictive of therapeutic outcomes associated with tumor sensitivity might be important for optimal treatment protocol selection. The aim of this study was to investigate the changes in gene expression in cell cycle-related genes that were induced by cisplatin, gemcitabine or a combined treatment using both agents in a low-grade urinary bladder transitional carcinoma cell line (RT4). The following three treatment protocols were used: 1.0 μM cisplatin, 1.56 μM gemcitabine and a combination of 1.0 μM cisplatin and 1.56 μM gemcitabine. Cytometry and morphology analysis (by phase-contrast photomicrography) were performed in addition to pathway-specific gene expression analysis using quantitative RT-PCR gene arrays. The following results were observed after 1.0 μM cisplatin treatment: (1) a decrease in cell number, (2) an increased percentage of scattered cells and (3) downregulated expression of genes related to cell cycle arrest, G1/S-to-mitotic cell cycle transition, DNA repair, apoptosis, transcription and mitosis. Treatment with 1.56 μM gemcitabine, or with both drugs simultaneously, induced the following effects: (1) a decrease in cell number, (2) an increased percentage of scattered and elongated cells, (3) the modulation of genes that are predominantly involved in DNA repair and (4) a significant upregulation of genes related to cell cycle arrest. Reduced cell density was observed after the combined treatment compared to the two other single-agent protocols. The downregulation of MRE11A and SKP2 was observed only in cells subjected to the combined treatment. In conclusion, cisplatin, gemcitabine and the combination of both drugs elicited distinct toxicogenomic effects in the RT4 bladder transitional carcinoma cell line, although disruptions in the expression of cell cycle control-related genes and other pathways responsible for cell survival were observed for all of the protocols. MRE11A and SKP2 downregulation appeared to be responsible for the synergistic therapeutic effects elicited by cisplatin and gemcitabine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cordon-Cardo C (2008) Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol 218:154–165

    Article  Google Scholar 

  2. Cheng L, Zhang S, MacLennan GT, Lopez-Beltran A, Montironi R (2011) Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol 42:455–481

    Article  CAS  PubMed  Google Scholar 

  3. Rink M, Cha EK, Green D, Hansen J, Robinson BD, Lotan Y, Sagalowsky AL, Chun FK, Karakiewicz PI, Fish M, Scherr DS, Shariat SF (2012) Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep 13:122–135

    Article  PubMed  Google Scholar 

  4. Gontijo AMMC, Marcondes JPC, Elias FN, de Oliveira ML, de Lima RO, Salvadori DM, de Camargo JL (2002) DNA Damage in cytologically normal urothelial cells of patients with a history of urothelial cell carcinoma. Environ Mol Mutagen 40:190–199

    Article  PubMed  Google Scholar 

  5. Belmut J, Albiol S, Ramirez de Olano A, Pujadas J, Maroto P, On behalf the Spanish Oncology Genitourinary Group (SOGUG) (2006) Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. Ann Oncol 17:113–117

    Article  Google Scholar 

  6. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev 4:307–319

    CAS  Google Scholar 

  7. Toschi L, Finocchiaro G, Gioia V (2005) Role of gemcitabine in cancer therapy. Future Oncol 1:7–17

    Article  CAS  PubMed  Google Scholar 

  8. Coppée JY (2008) Do DNA microarrays have their future behind them? Microbes Infect 10:1067–1071

    Article  PubMed  Google Scholar 

  9. Kraemer K, Schmidt U, Fuessel S, Herr A, Wirth MP, Meye A (2006) Microarray analyses in bladder cancer cells: inhibition of hTERT expression down-regulates EGFR. Int J Cancer 119:1276–1284

    Article  CAS  PubMed  Google Scholar 

  10. Missiaglia E, Donadelli M, Palmieri M, Crnogorac-Jurcevic T, Scarpa A, Lemoine NR (2005) Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2′-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene 24:199–211

    Article  CAS  PubMed  Google Scholar 

  11. Rabiaua N, Kossaïa M, Braud M, Chalabi N, Satih S, Bignon YJ, Bernard-Gallon DJ (2010) Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by polymerase chain reaction arrays in human prostate cancer cell lines. Cancer Epidemiol 34:200–206

    Article  Google Scholar 

  12. da Silva GN, de Camargo EA, Salvadori DM (2012) Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes. Mol Biol Rep 39:10373–10382

    Article  PubMed  Google Scholar 

  13. Tsunoda T, Koga H, Yokomizo A, Tatsugami K, Eto M, Inokuchi J, Hirata A, Masuda K, Okumura K, Naito S (2005) Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines. Oncogene 24:1396–1402

    Article  CAS  PubMed  Google Scholar 

  14. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, Namiki M, Kohri K, Matsushita Y, Fujioka T, Nakamura Y (2005) Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11:2625–2636

    Article  CAS  PubMed  Google Scholar 

  15. Da Silva GN, Marcondes JPC, Camargo EA, Sakamoto-Hojo ET, Passos GA, Salvadori DMF (2010) Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. Exp Med Biol 235:814–824

    Article  Google Scholar 

  16. Camargo EA, da Silva GN, Gobette CP, Marcondes JP, Salvadori DM (2013) No relationship between the amount of DNA damage and the level of hMLH1 and RASSF1A gene expression in bladder cancer cells treated with cisplatin and gemcitabine. Asian Pac J Cancer Prev 14:5941–5948

    Article  PubMed  Google Scholar 

  17. Gonçalves EM, Ventura CA, Yano T, Macedo MLR, Generi SC (2006) Morphological and growth alterations in vero cells transformed by cisplatin. Cell Biol Int 30:485–494

    Article  PubMed  Google Scholar 

  18. Sun T, Yang W, Liu J, Shen P (2011) Modeling the basal dynamics of p53 system. PLoS One 6:e27882

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Chen R, Feng C, Xu Y (2011) Cyclin-dependent kinase-associated protein Cks2 is associated with bladder cancer progression. J Int Med Res 39:533–540

    Article  CAS  PubMed  Google Scholar 

  20. Weis E, Schoen H, Victor A, Spix C, Ludwiq M, Scheneider-Raetzke B, Kohlschmidt N, Bartsch O, Gerhold-Ay A, Boehm N, Grus F, Haaf T, Galetzka D (2011) Reduced mRNA and protein expression of the genomic caretaker RAD9A in primary fibroblasts of individuals with childhood and independent second cancer. PLoS One 6:e25750

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Shigechi T, Tomida J, Sato K, Kobayashi M, Eykelenboom JK, Pessina F, Zhang Y, Uchida E, Ishiai M, Lowndes NF, Yamamoto K, Kurumizaka H, Maehara Y, Takata M (2012) ATR-ATRIP kinase complex triggers activation of the fanconi anemia DNA repair pathway. Cancer Res 72:1149–1156

    Article  CAS  PubMed  Google Scholar 

  22. Vilar E, Bartnik CM, Stenzel SL, Raskin L, Ahn J, Moreno V, Mukheriee B, Iniesta MD, Morgan MA, Rennert G, Gruber SB (2011) MRE11 deficiency increases sensitivity to poly (ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 71:2632–2642

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Martin DS, Bertino JR, Koutcher JA (2000) ATP depletion + pyrimidine depletion can markedly enhance cancer therapy: fresh insight for a new approach. Cancer Res 60:6776–6783

    CAS  PubMed  Google Scholar 

  24. Cepeda V, Fuertes MA, Castilha J, Alonso C, Quevedo C, Soto M, Perez JM (2006) Poly(ADP-Ribose) polymerase-1 (PARP-1). inhibitors in cancer chemotherapy. Recent Pat Anti-Cancer Drug Discov 1:39–53

    Article  CAS  Google Scholar 

  25. Wang G, Chan CH, Gao Y, Lin HK (2012) Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis. Chin J Cancer 31:169–177

    Article  PubMed Central  PubMed  Google Scholar 

  26. Hsieh HY, Shieh JJ, Chen CJ, Pan MY, Yang SY, Lin SC, Chang JS, Lee AY, Chang CC (2012) Prodigiosin down-regulates SKP2 to induce p27(KIP1) stabilization and antiproliferation in human lung adenocarcinoma cells. Br J Pharmacol 166:2095–2108

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo) and CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico), Brazil.

Conflict of interest

The authors declare that they have no conflict of interests.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Glenda Nicioli da Silva.

Rights and permissions

Reprints and permissions

About this article

Cite this article

da Silva, G.N., de Camargo, E.A., Sávio, A.L.V. et al. MRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells. Mol Biol Rep 41, 4613–4621 (2014). https://doi.org/10.1007/s11033-014-3332-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-014-3332-1

Keywords

Navigation